Atropine Protocols for Severe Bradycardia and Organophosphate Poisoning

Cardiac Indications – Severe Bradycardia

• The American College of Cardiology recommends an initial 0.5 mg IV push of atropine for symptomatic bradycardia with hemodynamic compromise, repeating 0.5 mg every 5 minutes as needed, up to a maximum cumulative dose of 2 mg (which achieves complete vagal blockade) 1.
• Peak hemodynamic effect of each IV dose occurs within 3 minutes of administration 1.
• Indications for atropine treatment include:
  
  • Sinus bradycardia with low cardiac output and peripheral hypoperfusion,
  • Symptomatic type I second‑degree AV block associated with inferior myocardial infarction,
  • Bradycardia accompanied by hypotension, confusion, or frequent premature ventricular contractions 1.
• Dose‑related cautions: doses < 0.5 mg IV should never be given because they can provoke paradoxical bradycardia via central vagal stimulation 1; atropine‑induced tachycardia may aggravate myocardial ischemia and therefore requires careful monitoring 1; atropine is rarely effective for type II second‑degree or third‑degree AV block at the His‑Purkinje level 1.
• If no clinical response is observed after the total 2 mg dose, immediate trans‑cutaneous pacing is advised 1.

Toxicologic Indications – Organophosphate Poisoning

• For organophosphate poisoning, initiate 1–2 mg IV atropine (adult) or 0.02 mg/kg IV (minimum 0.1 mg, maximum 0.5 mg per dose) for children, then double the dose every 5 minutes until atropinization endpoints are met 2.
• Escalation schedule (dose‑doubling every 5 minutes):
  
  • 2 mg → if ineffective, give 4 mg at 5 min,
  • 4 mg → if ineffective, give 8 mg at 10 min,
  • 8 mg → if ineffective, give 16 mg at 15 min,
  • Continue doubling until all endpoints are achieved 2.
• Atropinization endpoints (all must be present before stopping escalation):
• Typical cumulative doses: 10–20 mg within the first 2–3 hours; severe cases may require up to 50 mg in the first 24 hours 2.
• After achieving atropinization endpoints, transition to a continuous infusion at 10–20 % of the total loading dose per hour, not exceeding 2 mg/h in adults (e.g., a 20 mg loading dose → 2–4 mg/h infusion) 2. Continuous infusion is superior to intermittent boluses 2.
• Tachycardia is not a contraindication; escalation should continue despite elevated heart rate because the therapeutic goal is control of muscarinic symptoms, not normalization of heart rate [2][4].
• Concurrent therapy: administer pralidoxime alongside atropine—atropine alone is insufficient.
  
  • Adult regimen: 1–2 g IV loading dose over 15–30 minutes, then 400–600 mg/h continuous infusion;
  • Pediatric regimen: 25–50 mg/kg loading dose, then 10–20 mg/kg/h infusion 3. Pralidoxime reverses nicotinic effects (muscle weakness, paralysis) that atropine cannot address and must be given early before “aging” of the organophosphate‑enzyme bond [3][4].
• Seizure control: give benzodiazepines (e.g., diazepam 0.2 mg/kg IV or midazolam 0.05–0.1 mg/kg IV) 3.
• Airway management: perform early endotracheal intubation for life‑threatening poisoning; avoid succinylcholine or mivacurium because they are metabolized by cholinesterase and are contraindicated [3][4].
• Decontamination safety: health‑care workers must wear full personal protective equipment, remove contaminated clothing, and irrigate skin and wounds with soap and water; secondary exposure has caused severe poisoning requiring atropine and intubation [3][2].

Monitoring, Pitfalls, and Safety

• Never administer < 0.5 mg IV atropine for bradycardia (paradoxical worsening) 1; similarly, do not stop at 2 mg in organophosphate poisoning—the higher dosing protocol is required [1][2].
• Do not withhold atropine because of tachycardia; this is a dangerous error [2][4].
• Do not use fixed‑dose repetition in organophosphate poisoning; the protocol mandates dose‑doubling every 5 minutes 2.
• Do not delay pralidoxime; it must be given concurrently with atropine 3.
• Do not stop escalation when only heart rate is adequate; all five atropinization endpoints must be met 2.
• Expected adverse effect: high‑dose atropine may cause fever; this does not warrant cessation of therapy 2.
• Monitoring: continuous cardiac telemetry (to detect dysrhythmias without limiting dosing), respiratory assessments every 5–10 minutes during escalation, and observation for 48–72 hours for delayed complications or relapse 4. Check creatine kinase and potassium for possible rhabdomyolysis 2.